These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36004038)

  • 41. Atypical Pityriasis Rosea with Unilateral Presentation.
    Badakhsh H; Fadaei F; Badakhsh M; Balouchi A
    J Clin Diagn Res; 2016 Dec; 10(12):WD01-WD02. PubMed ID: 28208986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atypical pityriasis rosea: clinical evaluation of 27 patients.
    Kilinc F; Akbas A; Sener S; Aktaş A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):157-162. PubMed ID: 27558764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palmar herald patch in pityriasis rosea.
    Polat M; Yildirim Y; Makara A
    Australas J Dermatol; 2012 Aug; 53(3):e64-5. PubMed ID: 22881477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relapsing Pityriasis Rosea With HHV-7 Reactivation in an 11-Year-Old Girl.
    Engelmann I; Ogiez J; Ogiez L; Alidjinou EK; Lazrek M; Dewilde A; Hober D
    Pediatrics; 2018 May; 141(5):. PubMed ID: 29674359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pityriasis rosea: a natural history of pediatric cases in theCentral Anatolia Region of Turkey.
    Çölgeçen E; Kader Ç; Ulaş Y; Öztürk P; Küçük Ö; Balcı M
    Turk J Med Sci; 2016 Dec; 46(6):1740-1742. PubMed ID: 28081320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of Pityriasis rosea.
    Amatya A; Rajouria EA; Karn DK
    Kathmandu Univ Med J (KUMJ); 2012; 10(37):57-61. PubMed ID: 22971864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pityriasis Rosea: Clinical Profile from Central India.
    Chhabra N; Prabha N; Kulkarni S; Ganguly S
    Indian Dermatol Online J; 2018; 9(6):414-417. PubMed ID: 30505781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis.
    Chang HC; Sung CW; Lin MH
    J Dermatolog Treat; 2019 May; 30(3):288-293. PubMed ID: 30109959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year review of pityriasis rosea at the National Skin Centre, Singapore.
    Tay YK; Goh CL
    Ann Acad Med Singap; 1999 Nov; 28(6):829-31. PubMed ID: 10672397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pityriasis rosea calendar: a 7 year review of seasonal variation, age and sex distribution.
    Ayanlowo O; Akinkugbe A; Olumide Y
    Nig Q J Hosp Med; 2010; 20(1):29-31. PubMed ID: 20450028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
    Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
    Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interventions for pityriasis rosea.
    Contreras-Ruiz J; Peternel S; Jiménez Gutiérrez C; Culav-Koscak I; Reveiz L; Silbermann-Reynoso ML
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study.
    McMahon DE; Kovarik CL; Damsky W; Rosenbach M; Lipoff JB; Tyagi A; Chamberlin G; Fathy R; Nazarian RM; Desai SR; Lim HW; Thiers BH; Hruza GJ; French LE; Blumenthal K; Fox LP; Freeman EE
    J Am Acad Dermatol; 2022 Jan; 86(1):113-121. PubMed ID: 34517079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple attacks of transient monocular visual loss in a previously healthy man: a possible complication after COVID-19 vaccination?
    Cunha LP; Atalla Â; de Melo Costa-Neto J; Costa-Cunha LVF; Preti RC; Zacharias LC; Monteiro MLR
    Int J Retina Vitreous; 2022 Jun; 8(1):43. PubMed ID: 35725633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
    Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
    [No Abstract]   [Full Text] [Related]  

  • 60. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.